Aldeyra Therapeutics is a biotechnology company focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes. The Company has developed a series of product candidates that are designed specifically to trap and allow for the degradation of free aldehydes. Its most advanced product candidate is an eye drop formulation of NS2, which is under development for the treatment of Sjogren-Larsson Syndrome.